Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ATOSNASDAQ:BCABNASDAQ:CRBUNASDAQ:EXOZ On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeATOSAtossa Genetics$0.83-1.2%$0.85$0.55▼$1.66$109.68M0.9760,164 shs468,255 shsBCABBioAtla$0.38-4.5%$0.43$0.24▼$2.53$21.97M0.91916,612 shs1.33 million shsCRBUCaribou Biosciences$1.36-0.7%$1.08$0.66▼$3.00$127.42M2.481.33 million shs746,493 shsEXOZeXoZymes$9.91-2.8%$12.46$8.50▼$23.99$82.93MN/A10,270 shs1,256 shs13 Stocks Institutional Investors Won't Stop BuyingWhich stocks are hedge funds and endowments buying in today's market? Enter your email address and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying now.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceATOSAtossa Genetics0.00%-5.97%-3.81%+37.58%-29.32%BCABBioAtla0.00%-1.04%-16.79%+35.62%-73.43%CRBUCaribou Biosciences0.00%+7.94%+24.77%+77.20%-15.00%EXOZeXoZymes0.00%-4.62%-27.56%-0.40%+990,999,900.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationATOSAtossa Genetics1.4624 of 5 stars3.71.00.00.00.61.70.0BCABBioAtla2.6975 of 5 stars3.32.00.00.02.92.50.6CRBUCaribou Biosciences2.2979 of 5 stars3.51.00.00.02.71.70.6EXOZeXoZymesN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceATOSAtossa Genetics 3.33Buy$6.17645.67% UpsideBCABBioAtla 2.50Moderate Buy$5.001,215.79% UpsideCRBUCaribou Biosciences 3.00Buy$8.50525.00% UpsideEXOZeXoZymes 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest BCAB, ATOS, CRBU, and EXOZ Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/6/2025ATOSAtossa GeneticsAscendiant Capital MarketsSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$7.25 ➝ $7.506/5/2025ATOSAtossa GeneticsCraig HallumSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy$4.004/28/2025CRBUCaribou BiosciencesHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$9.00 ➝ $3.004/21/2025ATOSAtossa GeneticsAscendiant Capital MarketsSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$7.00 ➝ $7.25(Data available from 7/6/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookATOSAtossa GeneticsN/AN/AN/AN/A$0.57 per shareN/ABCABBioAtla$11M2.02N/AN/A$0.25 per share1.52CRBUCaribou Biosciences$9.99M12.66N/AN/A$2.79 per share0.49EXOZeXoZymesN/AN/AN/AN/A$1.25 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateATOSAtossa Genetics-$25.50M-$0.21N/AN/AN/AN/A-33.90%-31.53%8/11/2025 (Estimated)BCABBioAtla-$69.78M-$1.22N/AN/AN/AN/A-373.47%-116.55%8/6/2025 (Estimated)CRBUCaribou Biosciences-$149.10M-$1.62N/AN/AN/A-1,490.84%-55.70%-45.35%8/5/2025 (Estimated)EXOZeXoZymes-$5.86MN/A0.00∞N/AN/AN/AN/AN/ALatest BCAB, ATOS, CRBU, and EXOZ EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/13/2025Q1 2025ATOSAtossa Genetics-$0.06-$0.05+$0.01-$0.05N/AN/A5/12/2025Q1 2025EXOZeXoZymesN/A-$0.22N/A-$0.22N/AN/A5/8/2025Q1 2025CRBUCaribou Biosciences-$0.43-$0.43N/A-$0.43$1.48 million$2.35 million5/6/2025Q1 2025BCABBioAtla-$0.28-$0.29-$0.01-$0.26N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthATOSAtossa GeneticsN/AN/AN/AN/AN/ABCABBioAtlaN/AN/AN/AN/AN/ACRBUCaribou BiosciencesN/AN/AN/AN/AN/AEXOZeXoZymesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioATOSAtossa GeneticsN/A12.6712.67BCABBioAtlaN/A2.352.35CRBUCaribou BiosciencesN/A7.637.63EXOZeXoZymesN/A6.526.52Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipATOSAtossa Genetics12.74%BCABBioAtla77.23%CRBUCaribou Biosciences77.51%EXOZeXoZymesN/AInsider OwnershipCompanyInsider OwnershipATOSAtossa Genetics7.60%BCABBioAtla11.50%CRBUCaribou Biosciences8.28%EXOZeXoZymes72.41%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableATOSAtossa Genetics8129.17 million119.35 millionOptionableBCABBioAtla6058.42 million51.70 millionOptionableCRBUCaribou Biosciences10093.00 million85.30 millionOptionableEXOZeXoZymes298.37 million2.31 millionN/ABCAB, ATOS, CRBU, and EXOZ HeadlinesRecent News About These CompanieseXoZymes (NASDAQ:EXOZ) Shares Down 2.8% - Here's What HappenedJuly 4 at 4:35 AM | marketbeat.comInsider Buying: eXoZymes Inc. (NASDAQ:EXOZ) CEO Acquires 1,040 Shares of StockJuly 3 at 7:28 AM | insidertrades.comInsider Buying: eXoZymes Inc. (NASDAQ:EXOZ) CEO Purchases 1,040 Shares of StockJuly 2, 2025 | marketbeat.comeXoZymes Selected as Core Industry Partner in $9M NSF-Funded Initiative to Advance Modular Cell-Free BiomanufacturingJune 26, 2025 | accessnewswire.comAeXoZymes Increases CEO Compensation PackageJune 20, 2025 | tipranks.comExozymes (NASDAQ:EXOZ) Trading 3.9% Higher - Here's WhyJune 11, 2025 | marketbeat.comeXoZymes Highlights Scalable Biomanufacturing Platform and First Spinout, NCTx, on Grow Everything PodcastMay 16, 2025 | accessnewswire.comAeXoZymes Provides First Quarter 2025 and NCTx Subsidiary Update at 5PM EST TodayMay 12, 2025 | accessnewswire.comAeXoZymes to Host First Quarter 2025 and Subsidiary NCTx Update on Monday May 12, 2025, at 5PM ESTMay 7, 2025 | accessnewswire.comAeXoZymes Launches Subsidiary, NCTx, to Unlock a Promising Compound for Gut and Liver HealthMay 6, 2025 | accessnewswire.comABringing clarity and precision to the cell-free space by introducing exozymesApril 21, 2025 | globenewswire.comBioClick – an enzyme engineering game-changer, launched by eXoZymes and supported by a $300K NIH grantApril 10, 2025 | globenewswire.comeXoZymes Inc. Reports 2024 Progress and IPO SuccessApril 2, 2025 | tipranks.comeXoZymes appoints experienced biomanufacturing executive, Damien Perriman, as CCOApril 2, 2025 | globenewswire.comeXoZymes Provides Fourth Quarter and Full Year 2024 UpdateApril 2, 2025 | globenewswire.comeXoZymes to Host Fourth Quarter and Full Year 2024 Results Conference Call on Wednesday April 2, 2025March 26, 2025 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesWhy BigBear.ai Could Rally 100% and Catch Palantir SoonBy Gabriel Osorio-Mazilli | June 30, 2025View Why BigBear.ai Could Rally 100% and Catch Palantir SoonIPO Momentum Returns: 3 Stocks Rising After CoreWeave’s SurgeBy Dan Schmidt | June 20, 2025View IPO Momentum Returns: 3 Stocks Rising After CoreWeave’s SurgeBigBear.ai Poised to Benefit as Palantir Dominates AI DefenseBy Gabriel Osorio-Mazilli | June 23, 2025View BigBear.ai Poised to Benefit as Palantir Dominates AI DefenseIntel's Turnaround Strategy Shifts From Planning to Attack ModeBy Jeffrey Neal Johnson | June 20, 2025View Intel's Turnaround Strategy Shifts From Planning to Attack Mode2 Under the Radar Space & Defense Stocks With Huge PotentialBy Leo Miller | July 1, 2025View 2 Under the Radar Space & Defense Stocks With Huge PotentialBCAB, ATOS, CRBU, and EXOZ Company DescriptionsAtossa Genetics NASDAQ:ATOS$0.83 -0.01 (-1.21%) Closing price 07/3/2025 03:56 PM EasternExtended Trading$0.83 0.00 (-0.12%) As of 07/3/2025 04:40 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Atossa Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops medicines in the areas of unmet medical need in oncology for women breast cancer and other conditions in the United States. The company's lead drug candidate is oral (Z)-endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer. It also develops immunotherapy/chimeric antigen receptor therapy programs. The company was formerly known as Atossa Genetics Inc. and changed its name to Atossa Therapeutics, Inc. in January 2020. Atossa Therapeutics, Inc. was founded in 2008 and is headquartered in Seattle, Washington.BioAtla NASDAQ:BCAB$0.38 -0.02 (-4.45%) Closing price 07/3/2025 03:06 PM EasternExtended Trading$0.38 0.00 (0.00%) As of 07/3/2025 04:33 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.BioAtla, Inc., a clinical-stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. The company's lead clinical stage product candidates include mecbotamab vedotin (BA3011), a conditionally active biologic (CAB) antibody-drug conjugate (ADC), which is in Phase II clinical trial for treating undifferentiated pleomorphic sarcoma and non-small cell lung cancer (NSCLC); and ozuriftabmab vedotin (BA3021), a CAB ADC that is in Phase II clinical trial for the treatment of melanoma and squamous cell cancer of the head and neck. It is also developing Evalstotug (BA3071), a CAB anti-cytotoxic T-lymphocyte-associated antigen 4 antibody, which is in Phase II clinical trial for treating melanoma, carcinomas, and NSCLC; and BA3182, a bispecific candidate that is in Phase 1 study for the treatment of adenocarcinomas, as well as BA3361, which is in preclinical studies for treating multiple tumor types. The company was founded in 2007 and is headquartered in San Diego, California.Caribou Biosciences NASDAQ:CRBU$1.36 -0.01 (-0.73%) Closing price 07/3/2025 03:22 PM EasternExtended Trading$1.36 0.00 (0.00%) As of 07/3/2025 04:27 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Caribou Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies in the United States and internationally. Its lead product candidate is CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma. The company also develops CB-011, an allogeneic anti-BCMA CAR-T cell therapy that is in phase 1 clinical trial for the treatment of relapsed or refractory multiple myeloma; and CB-012, an allogeneic anti-CD371 CAR-T cell therapy that is in phase 1 clinical trial for the treatment of relapsed or refractory acute myeloid leukemia. Caribou Biosciences, Inc. was incorporated in 2011 and is headquartered in Berkeley, California.eXoZymes NASDAQ:EXOZ$9.91 -0.29 (-2.84%) As of 07/3/2025 01:00 PM EasterneXoZymes, Inc. is a development stage synthetic biochemical company. Its synthetic biology platform would enable the scalable exploration of many molecules and properties found in nature. The company was founded by Tyler Korman and Paul Opgenorth in April 2019 and is headquartered in Monrovia, NV. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 06/30 - 07/04 The Apple Comeback Will Be Better Than the Setback Micron’s Big Q3 Drives Applied Materials’ Bullish Outlook Why Occidental's Price Dip Signals a Buying Opportunity Qualcomm’s Hold Rating Misses Strong Growth Story Rigetti Computing: Cantor's Bullish Call May Be Just the Start Insider Selling at NVIDIA Could Turn Into an Opportunity Whiplash for Investors: AeroVironment's Confusing Stock Signals Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
